The US Food and Drug Administration said Tuesday it has approved the first drug made with a 3-D printer -- pills for treating epilepsy.
The Ohio-based company Aprecia Pharmaceuticals said its system can produce doses of up to 1,000 mg per tablet.
It said the product is a "porous formulation" that dissolves with just a sip of liquid, making it convenient for people who have trouble swallowing pills or for getting children to take medication.
FDA spokeswoman Sandy Walsh confirmed to AFP that the medication known as Spritam is the first made with a 3-D printer that the agency has approved.
Spritam, or Levetiracetam, has already been on the market for years in other formats, Walsh said.
Aprecia, which is not listed, plans to start distributing the medication in the first quarter of next year.
The FDA had already given the green light to other medical products made with such 3-D technology, such as prosthetic devices.
Aprecia said on its website that in coming years it plans to develop other kinds of medication with the new technology.
The health care industry is turning more and more to 3-D printers to produce custom-made implants for patients with rare pathologies or with certain kinds of injuries.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delaysMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor